Sep 2021 $6 M No. 7 $2 to $10 million 1
Blend Biosciences, Inc.: Raise no. 7, Sep 2021 × Investors in this round 1 investor had bought by the notice of Sep 27, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brian Roberts · Executive Officer, Director Aymeric Sallin · Director Dennis Ausiello · Director Guido Magni · Director Michael Metzger · Director Nilesh Kumar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Brian Roberts, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 27, 2021. Read the notice at the SEC .
equity SEC Dec 2020 $15 M No. 6 $10 to $50 million 8
Blend Biosciences, Inc.: Raise no. 6, Dec 2020 × Investors in this round 8 investors had bought by the notice of Dec 28, 2020: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $15 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brian Roberts · Executive Officer Aymeric Sallin · Director Dennis Ausiello · Director Guido Magni · Director Michael Metzger · Director Nilesh Kumar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Brian Roberts, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 28, 2020. Read the notice at the SEC .
equity SEC Dec 2019 $14 M No. 5 $10 to $50 million 13
Blend Biosciences, Inc.: Raise no. 5, Dec 2019 × Investors in this round 13 investors had bought by the notice of Dec 26, 2019: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $14 M of $14 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew J. Fromkin · Executive Officer, Director Aymeric J. Sallin · Director Dennis J. Ausiello · Director Guido J. Magni · Director Michael J. Metzger · Director Nilesh J. Kumar · Director Omid J. Farokhzad · Director Robert J. Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Andrew Fromkin, President. Source: SEC Form D, newest notice filed Dec 26, 2019. Read the notice at the SEC .
equity SEC Jan 2017 $30 M No. 4 $10 to $50 million 7
Blend Biosciences, Inc.: Raise no. 4, Jan 2017 × Investors in this round 7 investors had bought by the notice of Feb 9, 2017: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $30 M of $30 M offered
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew J. Fromkin · Executive Officer, Director Leila J. Alland · Executive Officer Richard J. Wooster · Executive Officer Aymeric S. Sallin · Director Dennis S. Ausiello · Director Frank S. Torti · Director Guido S. Magni · Director James J. Barrett · Director Nilesh J. Kumar · Director Omid J. Farokhzad · Director Robert S. Langer, Jr. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Andrew Fromkin, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 9, 2017. Read the notice at the SEC .
equity SEC Jan 2016 $38 M No. 3 $10 to $50 million 8
Blend Biosciences, Inc.: Raise no. 3, Jan 2016 × Investors in this round 8 investors had bought by the notice of Feb 9, 2017: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $38 M of $38 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $720,000
Paid to its own people $2,500,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks finders' fees and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Andrew Fromkin · Executive Officer, Director Leila C. Alland · Executive Officer Richard C. Wooster · Executive Officer Aymeric S. Sallin · Director Dennis C. Ausiello · Director Edwin M. Kania · Director Frank C. Torti · Director James Barrett · Director Nilesh C. Kumar · Director Omid C. Farokhzad · Director, Promoter Robert S. Langer · Director, Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round MTS Securities, LLC (CRD 104059) · New York, New York Sold in CA, CT, FL, IL, MA, NJ, NY, and outside the US Signed by Andrew Fromkin, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 9, 2017. Read the notice at the SEC .
equity, options SEC Dec 2012 $21 M No. 2 $10 to $50 million 9
Blend Biosciences, Inc.: Raise no. 2, Dec 2012 × Investors in this round 9 investors had bought by the notice of Dec 24, 2013: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $21 M of $21 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Mark S. Iwicki · Executive Officer, Director Aymeric S. Sallin · Director Edwin M. Kania · Director James Barrett · Director Omid C. Farokhzad · Director Peter Barton Hutt · Director Robert S. Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark Iwicki, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Dec 24, 2013. Read the notice at the SEC .
equity SEC Aug 2011 $3 M No. 1 $2 to $10 million 3
Blend Biosciences, Inc.: Raise no. 1, Aug 2011 × Investors in this round 3 investors had bought by the notice of Sep 2, 2011: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Barton Quillen · Executive Officer Shadi Barton Aryanpour · Executive Officer Aymeric S. Sallin · Director David S. Berry · Director James S. Barrett · Director Omid Farokhzad · Director Peter Barton Hutt · Director Robert S. Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jeffrey Quillen, Secretary. Source: SEC Form D, newest notice filed Sep 2, 2011. Read the notice at the SEC .
equity SEC